| Dear Voornaam
Welcome to your weekly Cancer Research UK Research Update email.
The Early Detection of Cancer Conference is returning to the UK on 1012 October 2023. If youre an early detection researcher or its a field youre interested in, join us in London for three days of stimulating scientific discussions and networking with experts across disciplines.
Fiona Walter from Queen Mary, University of London, Ramasamy Paulmurugan from the Canary Center at Stanford, and Julia Maxson from the OHSU Knight Cancer Institute are curating the scientific programme.
This years sold-out event drew over 400 attendees and 130 organisations from across the globe.
Save the date and sign up to be the first to hear when registration opens.
|
|
|---|
|
|---|
|
|
Funding & Research Opportunities |
|
|---|
|
|---|
| | | Applications accepted all-year round |
|
|---|
|
|---|
| | | Applications accepted all-year round |
|
|---|
|
|---|
|
|
 |
NOVARTIS PARTNERS WITH OUR CENTRE FOR DRUG DEVELOPMENT FOR PRECISION MEDICINE CLINICAL TRIAL This week, DETERMINE, our multi-drug, precision medicine trial designed to expand treatment options for patients with rare cancer, welcomes Novartis on board.
Providing access to initial treatment, Novartis joins Roche in making targeted therapeutics available to the rare cancer patients participating in the trial. Each new collaboration or partnership enables us to go further in advancing the field of rare cancer research and Novartis contribution marks the first major collaboration between our Centre for Drug Development and the company.
The Centre of Drug Development manages the trial in collaboration with University of Manchester and partners. The trial is currently recruiting both paediatric and adult patients with any of the 149 known rare cancer types. If you are interested in helping advance rare cancer research and development with your research-driven organisation, wed like to hear from you.
Find out more about the potential opportunities for genomic or diagnostic screening technologies and targeted clinical assets. |
|
|---|
|
|---|
|
|
 APPLICATIONS OPEN FOR TARGETED ONCOLOGY DEVELOPMENT PROGRAMME If you are a UK-based academic or part of an early-stage company with a defined oncology-focused innovation, take your next steps with our new Oncology Development Programme with Lean Life Science.
The programme, delivered in collaboration with four leading global pharma companies, Cancer Research Horizons (our innovation engine) and Manchester Cancer Research Centre, provides a proven pathway for you to convert your novel oncology ideas into commercially attractive assets that benefit patients.
Join one of our briefing calls to learn more about the opportunity. And apply by 19 January to receive critical insights from expert organisations from across the global research and development ecosystem. |
|
|---|
|  ABOUT TO PUBLISH YOUR RESEARCH? DONT FORGET TO KEEP US IN THE LOOP Are you preparing a Cancer Research UK-funded research paper for publication? If so, wed love to hear about it.
You can let us know about pending publications via our manuscript notification form. All information will be treated confidentially and wont be used without consulting you first.
Knowing in advance about upcoming publications helps us plan our communications and means we can better talk to our supporters about the work that their donations help fund.
|
|
|---|
|
|---|
|
|
CONNECT AND COLLABORATE WITH RESEARCHERS ACROSS THE UK Are you looking to exchange ideas, engage in lively discussions and explore opportunities with other research groups?
Join the Open Lab Initiative to connect with your research community and develop your project Open Lab now has over 300 members and has matched more than 100 research groups.
|
|
|---|
|
|---|
|
|
| | | Online 10:30 AM 10 January 2023 |
|
|---|
|
|---|
| | | London, UK 25 January 2023 |
|
|---|
|
|---|
| | | Cambridge, UK 9:00 AM 10 February 2023 |
|
|---|
|
|---|
| | | London, UK 10 October 2023 |
|
|---|
|
|---|
|
|
WHAT DID YOU THINK OF THIS EMAIL? We're always looking for ways to improve. Please give us your feedback by clicking below and leaving a comment. |
|
|---|
|
|---|
|
|
| Been forwarded this email?
Subscribe to our newsletter to stay up-to-date. |
|---|
| |
|---|
|
|
|
